Lurbinectedin is a novel anticancer agent that has been shown to have a synergistic effect with immunotherapy drugs. The mechanism of action of Lurbinectedin is that it inhibits the transcription factor complex, which is involved in DNA repair, and ultimately leads to cancer cell death [1].

A recent study published in Frontiers in Oncology investigated the effect of Lurbinectedin on the immune system and its potential to enhance the response to immunotherapy. The study found that Lurbinectedin can enhance the expression of tumor antigens and increase the infiltration of immune cells into the tumor microenvironment, which can lead to an improved response to immunotherapy [2].

Additionally, Lurbinectedin has been shown to increase the expression of PD-L1, a protein that is targeted by immune checkpoint inhibitors such as pembrolizumab and nivolumab. This increased expression of PD-L1 can lead to an improved response to these drugs [3].

In conclusion, Lurbinectedin has the potential to enhance the response to immunotherapy by increasing the expression of tumor antigens, increasing immune cell infiltration, and increasing the expression of PD-L1. Further research is needed to fully understand the mechanism of action of Lurbinectedin and its potential as a combination therapy with immunotherapy drugs [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.frontiersin.org/articles/10.3389/fonc.2023.1142081/full
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/